Skip to main content
Premium Trial:

Request an Annual Quote

Cisbio Inks Distribution Deal with Multispan

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cisbio will distribute Multispan's cell line portfolio in the US, under an agreement announced today by the firms.

The deal covers Multispan's cell line platform of more than 320 human and 209 rodent expression-ready cDNAs and 240 stable cell lines. The cell lines express G-protein coupled receptors in their native forms and "enable comprehensive investigation of effects of drug candidates on downstream signaling of each GPCR," the firms said in a joint statement.

Boston-based Cisbio will make the cell lines available to customers alongside its own platform for GPCR screening and cell surface receptor investigation.

According to the partners, the deal offers pharmaceutical and biotechnology researchers a new supply source of cell lines for functional assay development in GPCR drug development.

Further terms of the alliance were not disclosed.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.